The phase IV clinical study analyzes what interactions people who take Montelukast sodium and Nyquil have
1 These drugs include one enzyme inhibitor of 5-lipoxygenase (zileuton) and three chemically distinct cysteinyl leukotriene type I receptor antagonists
Montelukast sodium tablets are indicated for the relief of symptoms of seasonal allergic rhinitis in patients 15 years of age and older and perennial allergic rhinitis in patients 15 years of age and older
- Proton-pump inhibitor use is associated with a broad spectrum of neurological adverse events including impaired hearing, vision, and memory:
Montelukast sodium tablets are indicated for prevention of exercise-induced bronchoconstriction (EIB) in patients 15 years of age and older
Acute prevention of exercise-induced bronchoconstriction (EIB) in patients 15 years of age and older ( 1
A causal association between montelukast sodium and these underlying conditions has not Diarrhea ⇒ c (h)olestyramine; nystatin; montelukast; 5-HT 3 receptor inhibitors (e
Further studies and clinical trials are required to confirm Mechanism of Action
Montelukast sodium tablets are a leukotriene receptor antagonist indicated for: • Prophylaxis and chronic treatment of asthma in patients 15 years of age and older (1
The main symptoms of peripheral neuropathy can include: numbness and tingling in the feet or hands
The comparative pharmacokinetics of montelukast when administered as two 5 mg chewable tablets versus one 10 mg film-coated tablet have not been evaluated
13; 95% CI, 1
Relief of symptoms of allergic rhinitis (AR): seasonal allergic rhinitis (SAR) in patients 2
They included agitation, anxiety, depression, sleep disturbance, hallucinations, suicidal thinking and suicidality, tremor, dizziness, drowsiness, neuropathies and seizures